Immunological Exposure & Protection Gap Model
Comparative analysis of standard 2-dose accelerated protection versus multi-interval dose-splitting proposals.
Susceptible Window
900
Days unprotected / partial
Total Timeline
30
Months to complete series
Peak Antigen Load
15
Micrograms (mcg) per dose
Cumulative Exposure
75
Total antigen delivered (mcg)
Completion Feasibility & Drop-off Risk
Low (High drop-off risk over 30-month span)
Each additional required clinic visit compounds drop-off probability (~12% per interval). Over a 30-month regimen, completion rate plummets below 50%.
Interactive Injection Timeline (Months)
● Standard ACIP vs ■ Proposed Schedule
Proposed Splitting (5 Doses across 30 Months):
0m (Birth)
6m
12m
18m
24m
30m
Standard ACIP Baseline (2 Doses @ 2 & 4 Months):
0m
2m (Dose 1)
4m (Dose 2 - Full Immunity)
30m
| Evaluation Metric | Standard CDC/ACIP Schedule | Proposed 5-Dose / 6-Mo Split | Clinical Difference |
|---|---|---|---|
| Protection Latency (Susceptible Days) | 120 days (~4 months) | 900 days (30 months) | +780 days vulnerable |
| Peak Antigen Concentration | 15 mcg | 15 mcg | 0 mcg (identical per fraction) |
| Cumulative Antigen Burden | 30 mcg (2 doses) | 75 mcg (5 doses) | +45 mcg (+150% burden) |
| Adjuvant Multiplier | 1,010 mcg total | 2,525 mcg total | +150% additional adjuvant |
| Patient Adherence Forecast | 94% Completion | 42% Expected Completion | High attrition / drop-out |